Primary Sjögren Syndrome Clinical Trial
Official title:
Neurotrophins Implications in Primary Sjögren Syndrome
Neurotrophins (NTs) constitute a family of growth factors, which regulated differentiation,
proliferation, and survival of both neuronal cells and astrocytes. In recent years, several
studies have provided evidences that the cellular effects of NGF " Nerve Growth Factor ",
BDNF " Brain-Derived Neurotrophic Factor " and NT-3 are not limited to the nervous system.
Indeed, neurotrophins and their receptors are widely expressed on non neuronal cells. Data
concerning the implication of NTs and their receptors in the immune system maturation and in
the regulation of normal and pathological immune responses are numerous and suggest the
existence of a specific "neuro-immunomodulation" through these neuropeptides.
The aim of the study is to compare Sjögren's syndrome systemic activity to seric,
lymphocytic and conjunctival levels of NTs (i.e NGF, BDNF and NT-3). A preliminary study has
previously pointed out the link between high BDNF seric levels and Sjögren's systemic
activity. The increased levels of BDNF were correlated to T cell activation. A similar
correlation between high NGF level and hypergammaglobulinemia was also pointed out.
2 supplementary blood sample for determination of seric and lymphocytic NT profile will be
added to a standard biological analysis done for pSS follow- up.
Salivary sicca syndrome will be evaluated with un-stimulated salivary flow rate. Saliva
fluid will be collected from NTs levels determination (ELISA). Ocular sicca syndrome will be
evaluated by Schirmer tests and Lissaline green test. A conjunctival cytological impression
will be done in order to determine NTs conjunctival production by flow cytometry.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06440525 -
A Phase 2 Study of RSLV-132 in Females With Primary Sjögren's Syndrome
|
Phase 2 | |
| Not yet recruiting |
NCT03140111 -
LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients
|
N/A | |
| Not yet recruiting |
NCT06049368 -
68Ga-P16-093 PET/CT Imaging in the Salivary Gland
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03614299 -
Eye Dryness Evaluation in Primary Sjögren's Syndrome
|
||
| Not yet recruiting |
NCT03126383 -
Inflammatory Myopathies in Primary Sjögren's Syndrome
|
N/A | |
| Recruiting |
NCT04830644 -
A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.
|
Phase 2 | |
| Not yet recruiting |
NCT03765593 -
Biomarkers in Primary Sjögren's Syndrome
|
||
| Completed |
NCT05670535 -
Sjögren and Gynecologic Considerations
|
||
| Completed |
NCT03226444 -
Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT04816370 -
Effects of Primary Sjögren's Syndrome on Female Genitalia and Sexual Functions
|
N/A | |
| Completed |
NCT05380804 -
Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome
|
||
| Terminated |
NCT04700280 -
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
|
Phase 2 | |
| Completed |
NCT03130062 -
Resistance Exercise in Woman With Primary Sjörgen Syndrome.
|
N/A | |
| Completed |
NCT04093531 -
Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome
|
Phase 1 | |
| Recruiting |
NCT03509064 -
Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
|
||
| Completed |
NCT04224454 -
Vaccine Coverage and Primary Sjögren'Syndrome
|
||
| Completed |
NCT04960605 -
Prognosis of Dental Implants in Patients With Primary Sjögren's Syndrome
|
N/A | |
| Recruiting |
NCT06361745 -
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
|
N/A |